Heart Disease News and Research

Latest Heart Disease News and Research

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Many Rite Aid pharmacists have already been giving regular seasonal flu shots following the Centers for Disease Control and Prevention (CDC) advice that anyone who wishes to reduce the risk of getting the regular seasonal flu get a flu shot as soon as they are available.

31 Aug 2009

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

CLARIFY, the largest international registry to ever be carried out in stable coronary artery disease (CAD) patients was launched today in 40 countries, including Canada, at the European Society of Cardiology (ESC) Congress.

31 Aug 2009

SDBJ names A-Life Medical executive as the CFO of the Year

A-Life Medical, Inc., the pioneer and leading provider of computer-assisted coding products and services to the healthcare industry, announced today that Jaye Connolly, who serves as chief financial officer and chief operating officer, has been named CFO of the Year in the private company category of the 2009 San Diego Business Journal (SDBJ) CFO of the Year awards program.

31 Aug 2009

Navicure to provide clearinghouse services for three more clients

Navicure, a leading Internet-based medical claims clearinghouse for physician practices, today announced the addition of three South Carolina-based practices to its client roster. Lexington Heart Clinic, Premier Surgical Services, PA, and Sunshine Pediatrics all selected Navicure’s award-winning account receivables management solutions to help streamline and better manage the claims submission process.

31 Aug 2009

Health Net urges Americans to have their blood cholesterol measured

Tomorrow, September 1, marks the start of National Cholesterol Education Month. In support of this educational effort, Health Net, Inc., (NYSE: HNT) is encouraging those who haven't yet done so, to have their blood cholesterol measured and, if it's high, to embark on a cholesterol-lowering program.

31 Aug 2009

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

Researchers today published promising results for a drug that could lead to a replacement for the very effective but difficult-to-use blood thinner Coumadin (sold generically as Warfarin), currently taken by millions of Americans to reduce their risk of stroke.

31 Aug 2009

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon’s consulting and management organization with clinical expertise in the development of cardiovascular products and trials.

31 Aug 2009

Geron to present updates on product development programs at four investor conferences in September

Geron Corporation today announced that the company will present updates of its product development programs at four investor conferences in the month of September.

31 Aug 2009

DYSlipidemia International Study results presented at the ESC congress

According to a new analysis of 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. These results, from a study conducted by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., which operates in many countries as Merck Sharp & Dohme Limited, were presented today at the European Society of Cardiology (ESC) congress in Barcelona, Spain.

31 Aug 2009

Seasonal flu shots to be available daily without an appointment at more than 500 MinuteClinic locations

CVS/pharmacy, the nation's leading retail pharmacy, and MinuteClinic, the largest retail health care clinic provider in the U.S., today announced the availability of seasonal flu vaccinations and urged Americans to protect themselves early against the flu. CVS/pharmacy and MinuteClinic are divisions of CVS Caremark (NYSE: CVS), the largest provider of prescriptions in the country.

31 Aug 2009

First Edition: August 31, 2009

Today's headlines hint that summer's almost over, but the heat will still be on for health reform.

31 Aug 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

31 Aug 2009

New trial data shows that BIOTRONIK monitoring system is safe and effective for detecting patients' clinical events

BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced that new data from the TRUST (Lumos-T Safely Reduces Routine Office Device Follow Up) trial presented at the European Society of Cardiology Congress 2009 demonstrate the benefits of BIOTRONIK Home Monitoring in the early detection of patient clinical events as well as the safe reduction of in-office follow-up visits.

31 Aug 2009

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.

31 Aug 2009

Boston Scientific appoints Senior Vice President for its Cardiac Rhythm Management group

Boston Scientific Corporation (NYSE: BSX) today announced that Ken Stein, M.D., FACC, will join the Company as Senior Vice President and Associate Chief Medical Officer for its Cardiac Rhythm Management (CRM) group. Dr. Stein is currently the Associate Director of Clinical Cardiac Electrophysiology at Weill Cornell Medical Center and Associate Professor of Medicine at Cornell University.

31 Aug 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.

31 Aug 2009

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

31 Aug 2009

Intermediate dosages of otamixaban reduce acute coronary complications

30 Aug 2009

Clinical data of the REVERSE trial reveals how CRT improves functioning of the heart

Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.

30 Aug 2009

Heart Disease News and Research

Latest Heart Disease News and Research

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

SDBJ names A-Life Medical executive as the CFO of the Year

Navicure to provide clearinghouse services for three more clients

Health Net urges Americans to have their blood cholesterol measured

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Geron to present updates on product development programs at four investor conferences in September

DYSlipidemia International Study results presented at the ESC congress

Seasonal flu shots to be available daily without an appointment at more than 500 MinuteClinic locations

First Edition: August 31, 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

New trial data shows that BIOTRONIK monitoring system is safe and effective for detecting patients' clinical events

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Boston Scientific appoints Senior Vice President for its Cardiac Rhythm Management group

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Intermediate dosages of otamixaban reduce acute coronary complications

Clinical data of the REVERSE trial reveals how CRT improves functioning of the heart

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Heart Disease News and Research

Latest Heart Disease News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in